Age-Related Macular Degeneration Protocol

Eye HealthStrong Evidence

supplements

Primary

Supporting

Grade A

Studies

Primary Stack

Core supplements with strongest evidence

AREDS2 Formula (Lutein, Zeaxanthin, Vitamin C, E, Zinc, Copper)A

Standard AREDS2 formula daily

Evidence-based formula shown to reduce AMD progression by 25% in large clinical trials

2 studies8,500 participants

Supporting Studies (1)

PMID: 23644932 - AREDS2: Lutein + zeaxanthin and omega-3 in AMD (2013)

Supporting Stack

Additional supplements for enhanced results

LuteinA

10mg daily (part of AREDS2)

Macular pigment that filters damaging blue light and provides antioxidant protection

15 studies6,200 participants

ZeaxanthinA

2mg daily (part of AREDS2)

Concentrated in central macula; works synergistically with lutein for blue light protection

15 studies6,200 participants

Omega-3 Fatty Acids (DHA)B

1000mg DHA daily

DHA is concentrated in retinal photoreceptors; supports membrane fluidity and function

↓Cognitive Decline

8 studies4,200 participants

SaffronB

20-30mg daily

Crocin and crocetin provide retinal antioxidant protection; may improve visual function

Macular Thickness↑Retinal Function↑Visual acuity (VA)

5 studies180 participants

Supporting Studies (1)

PMID: 20688744 - Saffron supplementation in early AMD (2010)

How This Protocol Works

Simple Explanation

Age-related macular degeneration (AMD) damages the central part of the retina responsible for sharp, detailed vision. Oxidative stress and blue light damage are key drivers. This protocol is based on major clinical trials.

•AREDS2 formula is the only supplement proven in large trials to slow AMD progression. It reduced risk of advanced AMD by 25% over 5 years. The formula includes lutein (10mg), zeaxanthin (2mg), vitamin C (500mg), vitamin E (400 IU), zinc (80mg), and copper (2mg).

•Lutein and zeaxanthin are carotenoid pigments that concentrate in the macula, forming "natural sunglasses" that filter harmful blue light. Higher macular pigment density is protective.

•DHA (omega-3) is the primary structural fat in retinal photoreceptors. While the AREDS2 trial didn't show additional benefit, observational studies link high fish intake to lower AMD risk.

•Saffron is an emerging supplement that has shown improved visual function in early AMD studies—possibly through antioxidant and anti-inflammatory effects.

Expected timeline: Macular pigment increases over 3-6 months of supplementation. Slowing progression requires long-term (years) of consistent use.

Note: AREDS2 is for intermediate/advanced AMD—discuss with your ophthalmologist.

Clinical Perspective

AMD pathophysiology involves oxidative damage to RPE (retinal pigment epithelium), lipofuscin accumulation, drusen formation, and eventual photoreceptor loss. Geographic atrophy (dry) and choroidal neovascularization (wet) are advanced forms.

•AREDS2 formula (A-grade): Landmark NIH trial of 4,203 participants. 25% reduction in progression to advanced AMD. Replaced beta-carotene (lung cancer risk in smokers) with lutein/zeaxanthin (PMID: 23644932). Components:

•Lutein 10mg / Zeaxanthin 2mg: Macular pigments filtering 400-500nm blue light

•Vitamin C 500mg / Vitamin E 400 IU: Antioxidants

•Zinc 80mg / Copper 2mg: Zinc for RPE function; copper prevents deficiency from zinc

•Lutein/Zeaxanthin (A-grade): Xanthophyll carotenoids that accumulate in macula via specific binding proteins (GSTP1 for zeaxanthin). Increase macular pigment optical density (MPOD), correlating with reduced AMD risk.

•DHA (B-grade): Comprises 50% of photoreceptor outer segment fatty acids. AREDS2 showed no additive benefit, but may benefit those with low fish intake. Target: 1g DHA daily.

•Saffron (B-grade): Crocin/crocetin carotenoids with antioxidant and anti-inflammatory properties. RCTs show improved BCVA (best-corrected visual acuity) in early AMD (PMID: 20688744). Dose: 20mg/day.

Biomarkers: MPOD (macular pigment optical density), OCT imaging, visual acuity, contrast sensitivity.

Clinical context: AREDS2 formula indicated for intermediate AMD (large drusen) or advanced AMD in one eye. Wet AMD requires anti-VEGF injections—supplements don't replace this.

View All Protocols